IndicatorId,Indicator Name,CategoryId,Category
AFR0001,Average life expectancy at birth (in years),8,Male
AFR0001,Average life expectancy at birth (in years),9,Female
AFR0001,Average life expectancy at birth (in years),28,Both sexes (male and female)
AFR0002,Healthy life expectancy at birth (in years),8,Male
AFR0002,Healthy life expectancy at birth (in years),9,Female
AFR0002,Healthy life expectancy at birth (in years),28,Both sexes (male and female)
AFR0003,Life expectancy at age 60 years,8,Male
AFR0003,Life expectancy at age 60 years,9,Female
AFR0003,Life expectancy at age 60 years,28,Both sexes (male and female)
AFR0004,Population size (in thousands) total,8,Male
AFR0004,Population size (in thousands) total,9,Female
AFR0004,Population size (in thousands) total,28,Both sexes (male and female)
AFR0004,Population size (in thousands) total,29,Total
AFR0005,Crude death rate (per 1 000 mid-year population),28,Both sexes (male and female)
AFR0006,Adolescent mortality rate (per 100 000 adolescent population),8,Male
AFR0006,Adolescent mortality rate (per 100 000 adolescent population),9,Female
AFR0006,Adolescent mortality rate (per 100 000 adolescent population),28,Both sexes (male and female)
AFR0007,Adult mortality rate between 15 and 60 years of age (per 1000 population),8,Male
AFR0007,Adult mortality rate between 15 and 60 years of age (per 1000 population),9,Female
AFR0007,Adult mortality rate between 15 and 60 years of age (per 1000 population),28,Both sexes (male and female)
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],3,Under Fives ( 0-4 Years)
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],8,Male
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],9,Female
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],11,Rural
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],12,Urban
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],28,Both sexes (male and female)
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],70,0-4 years
AFR0008,Under-five mortality rate (per 1 000 live births)-[SDG 3.2.1],1090,Both sexes 0-5 years
AFR0009,Infant mortality rate (per 1 000 live births),2,Infants (0-11 Months)
AFR0009,Infant mortality rate (per 1 000 live births),8,Male
AFR0009,Infant mortality rate (per 1 000 live births),9,Female
AFR0009,Infant mortality rate (per 1 000 live births),11,Rural
AFR0009,Infant mortality rate (per 1 000 live births),12,Urban
AFR0009,Infant mortality rate (per 1 000 live births),28,Both sexes (male and female)
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],1,Neonate (0-28 Days)
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],8,Male
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],9,Female
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],11,Rural
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],12,Urban
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],28,Both sexes (male and female)
AFR0010,Neonatal mortality rate (per 1 000 live births)-[SDG 3.2.2],1004,Both sexes (0-28 Days)
AFR0011,Stillbirth rate (per 1000 total births),2,Infants (0-11 Months)
AFR0011,Stillbirth rate (per 1000 total births),9,Female
AFR0011,Stillbirth rate (per 1000 total births),11,Rural
AFR0011,Stillbirth rate (per 1000 total births),12,Urban
AFR0011,Stillbirth rate (per 1000 total births),28,Both sexes (male and female)
AFR0011,Stillbirth rate (per 1000 total births),29,Total
AFR0011,Stillbirth rate (per 1000 total births),1051,<20years
AFR0011,Stillbirth rate (per 1000 total births),1052,20-29 years
AFR0011,Stillbirth rate (per 1000 total births),1053,30-39 years
AFR0011,Stillbirth rate (per 1000 total births),1054,40-49 years
AFR0012,"Maternal mortality ratio (per 100,000 live births) [SDG 3.1.1]",9,Female
AFR0012,"Maternal mortality ratio (per 100,000 live births) [SDG 3.1.1]",29,Total
AFR0012,"Maternal mortality ratio (per 100,000 live births) [SDG 3.1.1]",66,Female (15-49 years)
AFR0013,TB mortality rate (per 100 000 population),28,Both sexes (male and female)
AFR0013,TB mortality rate (per 100 000 population),29,Total
AFR0014,AIDS-related mortality rate (per 100 000 population),28,Both sexes (male and female)
AFR0014,AIDS-related mortality rate (per 100 000 population),29,Total
AFR0015,Malaria mortality rate (per 100 000 population),28,Both sexes (male and female)
AFR0015,Malaria mortality rate (per 100 000 population),999,Not Applicable
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],6,Adult (15+ Years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],8,Male
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],9,Female
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],28,Both sexes (male and female)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],35,Male (15-24 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],36,Female (15-24 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],37,Both sexes (15-24 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],42,Female (15+ years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],45,Male (15+ years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],105,Male (85+ years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],123,Female (85+ years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],999,Not Applicable
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1107,Both sexes (85+ years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1108,Both sexes (25-34 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1109,Both sexes (35-44 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1110,Both sexes (45-54 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1111,Both sexes (55-64 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1112,Both sexes (65-74 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1113,Both sexes (75-84 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1114,Female (25-34 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1115,Female (35-44 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1116,Female (45-54 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1117,Female (55-64 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1118,Female (65-74 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1120,Male (25-34 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1121,Male (35-44 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1122,Male (45-54 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1123,Male (55-64 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1124,Male (65-74 years)
AFR0016,Suicide rate (per 100 000 population) - [SDG 3.4.2],1125,Male (75-84 years)
AFR0017,Death rate due to road traffic injuries (per 100 000 population) [SDG 3.6.1],8,Male
AFR0017,Death rate due to road traffic injuries (per 100 000 population) [SDG 3.6.1],9,Female
AFR0017,Death rate due to road traffic injuries (per 100 000 population) [SDG 3.6.1],28,Both sexes (male and female)
AFR0017,Death rate due to road traffic injuries (per 100 000 population) [SDG 3.6.1],29,Total
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),2,Infants (0-11 Months)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),27,65+ years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),70,0-4 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),71,5-9 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),72,10-14 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),73,15-19 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),74,20-24 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),75,25-29 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),76,30-34 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),77,35-39 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),78,40-44 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),79,45-49 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),80,50-54 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),81,55-59 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),82,60-64 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),83,65-69 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),84,70-74 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),85,75-79 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),86,80-84 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),87,85+ years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),88,Male (0-4 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),89,Male (5-9 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),90,Male (10-14 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),91,Male ((15-19 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),92,Male (20-24 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),93,Male (25-29 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),94,Male (30-34 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),95,Male (35-39 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),96,Male (40-44 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),97,Male (45-49 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),98,Male (50-54 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),99,Male (55-59 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),100,Male (60-64 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),101,Male (65-69 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),102,Male (70-74 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),103,Male (75-79 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),104,Male (80-84 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),105,Male (85+ years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),106,Female (0-4 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),107,Female (10-14 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),108,Female (5-9 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),109,Female (15-19 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),110,Female (20-24 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),111,Female (25-29 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),112,Female (30-34 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),113,Female (35-39 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),114,Female (40-44 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),115,Female (45-49 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),116,Female (50-54 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),117,Female (55-59 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),118,Female (60-64 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),119,Female (65-69 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),120,Female (70-74 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),121,Female (75-79 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),122,Female (80-84 years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),123,Female (85+ years)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1009,100+ years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1010,85-89 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1011,90-94 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1012,95-99 years
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1015,<12 months
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1087,Female (<1year)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1088,Male (<1 year)
AFR0018,Population by age (under 1; 1-5; 6-12; 13-25; 26-49; 50-64; over 65 years),1090,Both sexes 0-5 years
AFR0019,Number of people living with HIV,6,Adult (15+ Years)
AFR0019,Number of people living with HIV,25,0-14 years
AFR0019,Number of people living with HIV,28,Both sexes (male and female)
AFR0019,Number of people living with HIV,29,Total
AFR0020,HIV prevalence rate (per 1000 population),6,Adult (15+ Years)
AFR0020,HIV prevalence rate (per 1000 population),28,Both sexes (male and female)
AFR0020,HIV prevalence rate (per 1000 population),29,Total
AFR0020,HIV prevalence rate (per 1000 population),35,Male (15-24 years)
AFR0020,HIV prevalence rate (per 1000 population),36,Female (15-24 years)
AFR0020,HIV prevalence rate (per 1000 population),37,Both sexes (15-24 years)
AFR0020,HIV prevalence rate (per 1000 population),42,Female (15+ years)
AFR0020,HIV prevalence rate (per 1000 population),45,Male (15+ years)
AFR0020,HIV prevalence rate (per 1000 population),65,Both sexes (15-49 yeras)
AFR0020,HIV prevalence rate (per 1000 population),66,Female (15-49 years)
AFR0020,HIV prevalence rate (per 1000 population),67,Male (15-49 years)
AFR0021,Prevalence of obesity in persons aged 18+years,28,Both sexes (male and female)
AFR0021,Prevalence of obesity in persons aged 18+years,29,Total
AFR0023,Proportion of population using improved drinking-water sources (%),8,Male
AFR0023,Proportion of population using improved drinking-water sources (%),9,Female
AFR0023,Proportion of population using improved drinking-water sources (%),11,Rural
AFR0023,Proportion of population using improved drinking-water sources (%),12,Urban
AFR0023,Proportion of population using improved drinking-water sources (%),28,Both sexes (male and female)
AFR0023,Proportion of population using improved drinking-water sources (%),29,Total
AFR0024,Proportion of population using improved sanitation (%),8,Male
AFR0024,Proportion of population using improved sanitation (%),9,Female
AFR0024,Proportion of population using improved sanitation (%),11,Rural
AFR0024,Proportion of population using improved sanitation (%),12,Urban
AFR0024,Proportion of population using improved sanitation (%),28,Both sexes (male and female)
AFR0024,Proportion of population using improved sanitation (%),29,Total
AFR0024,Proportion of population using improved sanitation (%),1066,National-Safety managed
AFR0024,Proportion of population using improved sanitation (%),1067,National-Disposal in situ
AFR0024,Proportion of population using improved sanitation (%),1068,National-Empiled and treated
AFR0024,Proportion of population using improved sanitation (%),1069,National-Wastewater treated
AFR0024,Proportion of population using improved sanitation (%),1070,National-Latrines and other
AFR0024,Proportion of population using improved sanitation (%),1071,National-Septic tanks
AFR0024,Proportion of population using improved sanitation (%),1072,National-Sewer connections
AFR0024,Proportion of population using improved sanitation (%),1073,Rural-Safety managed
AFR0024,Proportion of population using improved sanitation (%),1074,Rural-Disposal in situ
AFR0024,Proportion of population using improved sanitation (%),1075,Rural-Empiled and treated
AFR0024,Proportion of population using improved sanitation (%),1076,Rural-Wastewater treated
AFR0024,Proportion of population using improved sanitation (%),1077,Rural-Latrines and other
AFR0024,Proportion of population using improved sanitation (%),1078,Rural-Septic tanks
AFR0024,Proportion of population using improved sanitation (%),1079,Rural-Sewer connections
AFR0024,Proportion of population using improved sanitation (%),1080,Urban-Safety managed
AFR0024,Proportion of population using improved sanitation (%),1081,Urban-Disposal in situ
AFR0024,Proportion of population using improved sanitation (%),1082,Urban-Empiled and treated
AFR0024,Proportion of population using improved sanitation (%),1083,Urban-Wastewater treated
AFR0024,Proportion of population using improved sanitation (%),1084,Urban-Latrines and other
AFR0024,Proportion of population using improved sanitation (%),1085,Urban-Septic tanks
AFR0024,Proportion of population using improved sanitation (%),1086,Urban-Sewer connections
AFR0025,People practicing open defecation (%) of population),11,Rural
AFR0025,People practicing open defecation (%) of population),12,Urban
AFR0025,People practicing open defecation (%) of population),28,Both sexes (male and female)
AFR0025,People practicing open defecation (%) of population),29,Total
AFR0026,Annual mean concentrations of fine particulate matter (PM2.5) in urban areasÂ (µg/m3),12,Urban
AFR0026,Annual mean concentrations of fine particulate matter (PM2.5) in urban areasÂ (µg/m3),29,Total
AFR0026,Annual mean concentrations of fine particulate matter (PM2.5) in urban areasÂ (µg/m3),999,Not Applicable
AFR0027,Average death rate due to natural disasters y (per 100 000 population),28,Both sexes (male and female)
AFR0027,Average death rate due to natural disasters y (per 100 000 population),29,Total
AFR0028,Number of victims of intentional homicide per 100 000 population,8,Male
AFR0028,Number of victims of intentional homicide per 100 000 population,9,Female
AFR0028,Number of victims of intentional homicide per 100 000 population,28,Both sexes (male and female)
AFR0029,Estimated direct deaths from major conflicts (per 100 000 population),8,Male
AFR0029,Estimated direct deaths from major conflicts (per 100 000 population),9,Female
AFR0029,Estimated direct deaths from major conflicts (per 100 000 population),28,Both sexes (male and female)
AFR0030,"Children in employment, total (% of children ages 7-14)",8,Male
AFR0030,"Children in employment, total (% of children ages 7-14)",9,Female
AFR0030,"Children in employment, total (% of children ages 7-14)",28,Both sexes (male and female)
AFR0030,"Children in employment, total (% of children ages 7-14)",1039,5-14 years
AFR0031,Net official development assistance received (current US$),999,Not Applicable
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",8,Male
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",9,Female
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",11,Rural
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",12,Urban
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",28,Both sexes (male and female)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",29,Total
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",35,Male (15-24 years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",36,Female (15-24 years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",37,Both sexes (15-24 years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",38,Both sexes (25+ years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",39,Male (25+ years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",40,Female (25+ years)
AFR0032,"Unemployment, total (% of total labor force) (modelled ILO estimate)",999,Not Applicable
AFR0033,Individuals using the Internet (% of population),8,Male
AFR0033,Individuals using the Internet (% of population),9,Female
AFR0033,Individuals using the Internet (% of population),28,Both sexes (male and female)
AFR0033,Individuals using the Internet (% of population),29,Total
AFR0034,Proportion of seats held by women in national parliaments (%),9,Female
AFR0034,Proportion of seats held by women in national parliaments (%),66,Female (15-49 years)
AFR0035,"IHR Coordination, Communication and Advocacy",28,Both sexes (male and female)
AFR0035,"IHR Coordination, Communication and Advocacy",29,Total
AFR0035,"IHR Coordination, Communication and Advocacy",999,Not Applicable
AFR0036,Real Time Surveillance,29,Total
AFR0036,Real Time Surveillance,999,Not Applicable
AFR0039,Risk Communication,29,Total
AFR0039,Risk Communication,999,Not Applicable
AFR0047,Availability of basic amenities (%),29,Total
AFR0047,Availability of basic amenities (%),999,Not Applicable
AFR0049,Service availability index (%),29,Total
AFR0049,Service availability index (%),999,Not Applicable
AFR0050,Prevention of mother-to-child transmission (PMTCT) of HIV,9,Female
AFR0050,Prevention of mother-to-child transmission (PMTCT) of HIV,29,Total
AFR0050,Prevention of mother-to-child transmission (PMTCT) of HIV,42,Female (15+ years)
AFR0052,Proportion of the population with large household expenditure on health as a share of total household consumption or income [SDG 3.8.2],11,Rural
AFR0052,Proportion of the population with large household expenditure on health as a share of total household consumption or income [SDG 3.8.2],12,Urban
AFR0052,Proportion of the population with large household expenditure on health as a share of total household consumption or income [SDG 3.8.2],29,Total
AFR0052,Proportion of the population with large household expenditure on health as a share of total household consumption or income [SDG 3.8.2],999,Not Applicable
AFR0055,Intimate partner violence and injuries,9,Female
AFR0055,Intimate partner violence and injuries,11,Rural
AFR0055,Intimate partner violence and injuries,12,Urban
AFR0055,Intimate partner violence and injuries,73,15-19 years
AFR0055,Intimate partner violence and injuries,74,20-24 years
AFR0055,Intimate partner violence and injuries,75,25-29 years
AFR0055,Intimate partner violence and injuries,1053,30-39 years
AFR0055,Intimate partner violence and injuries,1054,40-49 years
AFR0056,Smoking (%),28,Both sexes (male and female)
AFR0056,Smoking (%),66,Female (15-49 years)
AFR0056,Smoking (%),67,Male (15-49 years)
AFR0056,Smoking (%),98,Male (50-54 years)
AFR0058,Private Insurance as % of Private Health Expenditure (PvtHE),29,Total
AFR0058,Private Insurance as % of Private Health Expenditure (PvtHE),999,Not Applicable
AFR0059,Availability of national list of approved medical devices for procurement or reimbursement,999,Not Applicable
AFR0060,Availability of national standards or recommended lists of medical devices,999,Not Applicable
AFR0061,Availability of technical specifications of medical devices to support procurement or donations,999,Not Applicable
AFR0062,Civil registration coverage of births (%),3,Under Fives ( 0-4 Years)
AFR0062,Civil registration coverage of births (%),28,Both sexes (male and female)
AFR0062,Civil registration coverage of births (%),999,Not Applicable
AFR0062,Civil registration coverage of births (%),1042,>5 years
AFR0063,Civil registration coverage of cause-of-death (%),999,Not Applicable
AFR0064,Community and traditional health workers density (per 1000 population),28,Both sexes (male and female)
AFR0064,Community and traditional health workers density (per 1000 population),999,Not Applicable
AFR0065,Health Capital Expenditure (HK) % Gross Domestic Product (GDP),999,Not Applicable
AFR0066,Other health workers density (per 1000 population),28,Both sexes (male and female)
AFR0066,Other health workers density (per 1000 population),29,Total
AFR0066,Other health workers density (per 1000 population),999,Not Applicable
AFR0067,Other Private Health Expenditure (OTHER) as % Current Health Expenditure (CHE),999,Not Applicable
AFR0068,Out-of-pocket (OOPS) as % of Private health expenditure (PvtHE),999,Not Applicable
AFR0069,Out-of-Pocket Expenditure (OOPS) per Capita in PPP Int$,999,Not Applicable
AFR0070,Out-of-Pocket Expenditure (OOPS) per Capita in US$,999,Not Applicable
AFR0071,Total density per 100 000 population: District/rural hospitals,29,Total
AFR0071,Total density per 100 000 population: District/rural hospitals,999,Not Applicable
AFR0072,Total density per 100 000 population: Health centres,29,Total
AFR0072,Total density per 100 000 population: Health centres,58,Mumps
AFR0072,Total density per 100 000 population: Health centres,999,Not Applicable
AFR0073,Total density per 100 000 population: Health posts,29,Total
AFR0073,Total density per 100 000 population: Health posts,999,Not Applicable
AFR0074,Total density per 100 000 population: Hospitals,29,Total
AFR0074,Total density per 100 000 population: Hospitals,999,Not Applicable
AFR0075,Total density per 100 000 population: Provincial hospitals,29,Total
AFR0075,Total density per 100 000 population: Provincial hospitals,999,Not Applicable
AFR0076,Total density per 100 000 population: Specialized hospitals,29,Total
AFR0076,Total density per 100 000 population: Specialized hospitals,999,Not Applicable
AFR0077,Total density per million females aged from 50 to 69 years old: Mammography units,999,Not Applicable
AFR0078,Total density per million population: Computed tomography units,999,Not Applicable
AFR0079,Total density per million population: Gamma camera or Nuclear medicine,999,Not Applicable
AFR0080,Total density per million population: Linear Accelerator (numeric),999,Not Applicable
AFR0081,Total density per million population: Magnetic Resonance Imaging,999,Not Applicable
AFR0082,Total density per million population: Positron Emission tomography,999,Not Applicable
AFR0083,Total density per million population: Radiotherapy units,999,Not Applicable
AFR0084,Total density per million population: Telecobalt Unit,999,Not Applicable
AFR0085,Types of lists recommending health technology for high burden diseases,999,Not Applicable
AFR0086,Healthy life expectancy (HALE) at age 60 (years),8,Male
AFR0086,Healthy life expectancy (HALE) at age 60 (years),9,Female
AFR0086,Healthy life expectancy (HALE) at age 60 (years),28,Both sexes (male and female)
AFR0087,Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%),28,Both sexes (male and female)
AFR0087,Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%),999,Not Applicable
AFR0088,Domestic General Government Health Expenditure (GGHE-D) as % Gross Domestic Product (GDP),999,Not Applicable
AFR0089,Domestic General Government Health Expenditure (GGHE-D) per Capita in PPP Int$,999,Not Applicable
AFR0090,Domestic General Government Health Expenditure (GGHE-D) per Capita in US$,999,Not Applicable
AFR0091,Domestic Private Health Expenditure (PVT-D) per Capita in PPP Int$,999,Not Applicable
AFR0092,Domestic Private Health Expenditure (PVT-D) per Capita in US$,999,Not Applicable
AFR0093,External Health Expenditure (EXT) as % of Current Health Expenditure (CHE),999,Not Applicable
AFR0094,External Health Expenditure (EXT) per Capita in PPP Int$,999,Not Applicable
AFR0095,External Health Expenditure (EXT) per Capita in US$,999,Not Applicable
AFR0096,Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2),8,Male
AFR0096,Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2),9,Female
AFR0096,Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2),28,Both sexes (male and female)
AFR0097,Domestic Health Expenditure (DOM) as % of Current Health Expenditure (CHE),109,Female (15-19 years)
AFR0097,Domestic Health Expenditure (DOM) as % of Current Health Expenditure (CHE),999,Not Applicable
AFR0098,Proportion of population living below the national poverty line (%),8,Male
AFR0098,Proportion of population living below the national poverty line (%),9,Female
AFR0098,Proportion of population living below the national poverty line (%),11,Rural
AFR0098,Proportion of population living below the national poverty line (%),12,Urban
AFR0098,Proportion of population living below the national poverty line (%),27,65+ years
AFR0098,Proportion of population living below the national poverty line (%),28,Both sexes (male and female)
AFR0098,Proportion of population living below the national poverty line (%),29,Total
AFR0098,Proportion of population living below the national poverty line (%),70,0-4 years
AFR0098,Proportion of population living below the national poverty line (%),1039,5-14 years
AFR0099,Prevalence of undernourishment (%) [SDG 2.1.1],28,Both sexes (male and female)
AFR0100,Proportion of children moderately or severely stunted (%),28,Both sexes (male and female)
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",9,Female
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",11,Rural
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",12,Urban
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",66,Female (15-49 years)
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",73,15-19 years
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",74,20-24 years
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",75,25-29 years
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",1052,20-29 years
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",1053,30-39 years
AFR0101,"Proportion of ever-partnered women and girls subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, by age (%)",1054,40-49 years
AFR0102,Proportion of women aged 20-24 years who were married or in a union by age 18 (%),9,Female
AFR0103,"Proportion of girls and women aged 15-49 years who have undergone female genital mutilation/cutting, by age (%)",9,Female
AFR0104,"Number of new HIV infections per 1,000 uninfected population",6,Adult (15+ Years)
AFR0104,"Number of new HIV infections per 1,000 uninfected population",8,Male
AFR0104,"Number of new HIV infections per 1,000 uninfected population",9,Female
AFR0104,"Number of new HIV infections per 1,000 uninfected population",25,0-14 years
AFR0104,"Number of new HIV infections per 1,000 uninfected population",28,Both sexes (male and female)
AFR0104,"Number of new HIV infections per 1,000 uninfected population",29,Total
AFR0105,Proportion of women married or in a union of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (% of women aged 15-49 years),9,Female
AFR0105,Proportion of women married or in a union of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (% of women aged 15-49 years),66,Female (15-49 years)
AFR0106,"Adolescent birth rate (per 1,000 women aged 15-19 years)",5,Adolescents (10-19 Years)
AFR0106,"Adolescent birth rate (per 1,000 women aged 15-19 years)",9,Female
AFR0106,"Adolescent birth rate (per 1,000 women aged 15-19 years)",109,Female (15-19 years)
AFR0107,Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%),11,Rural
AFR0107,Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%),12,Urban
AFR0107,Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%),28,Both sexes (male and female)
AFR0107,Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%),29,Total
AFR0107,Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%),999,Not Applicable
AFR0108,"Mortality rate attributed to household air pollution (deaths per 100,000 population)",28,Both sexes (male and female)
AFR0109,"Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)",8,Male
AFR0109,"Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)",9,Female
AFR0109,"Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)",28,Both sexes (male and female)
AFR0109,"Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)",29,Total
AFR0110,Mortality rate attributed to unintentional poisoning [SDG 3.9.3],8,Male
AFR0110,Mortality rate attributed to unintentional poisoning [SDG 3.9.3],9,Female
AFR0110,Mortality rate attributed to unintentional poisoning [SDG 3.9.3],28,Both sexes (male and female)
AFR0111,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%),28,Both sexes (male and female)
AFR0111,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%),29,Total
AFR0112,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%),2,Infants (0-11 Months)
AFR0112,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%),28,Both sexes (male and female)
AFR0112,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%),29,Total
AFR0112,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%),999,Not Applicable
AFR0113,"Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries (millions of constant 2016 United States dollars)",28,Both sexes (male and female)
AFR0113,"Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries (millions of constant 2016 United States dollars)",999,Not Applicable
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",30,Nursing and midwifery
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",32,Dentistry
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",1000,Dentists
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",1001,Medical doctors
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",1002,Nursing and midwifery personnel
AFR0114,"Health worker density, by type of occupation (per 10,000 population)",1003,Pharmacists
AFR0115,"Proportion of population using safely managed drinking water services, by urban/rural (%)",11,Rural
AFR0115,"Proportion of population using safely managed drinking water services, by urban/rural (%)",12,Urban
AFR0115,"Proportion of population using safely managed drinking water services, by urban/rural (%)",28,Both sexes (male and female)
AFR0115,"Proportion of population using safely managed drinking water services, by urban/rural (%)",29,Total
AFR0117,Proportion of bodies of water with good ambient water quality (%),29,Total
AFR0118,Proportion of urban population living in slums (%),28,Both sexes (male and female)
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",28,Both sexes (male and female)
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",29,Total
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",124,Geophysical
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",125,Biological
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",126,Hydrological
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",127,Meteorological
AFR0119,"Number of deaths and missing persons attributed to disasters, by hazard type (number)",128,Climatological
AFR0121,"Annual mean levels of fine particulate matter in cities, urban population (micrograms per cubic meter)",29,Total
AFR0125,PCV3 immunization coverage among 1-year-olds (%),2,Infants (0-11 Months)
AFR0125,PCV3 immunization coverage among 1-year-olds (%),28,Both sexes (male and female)
AFR0125,PCV3 immunization coverage among 1-year-olds (%),29,Total
AFR0125,PCV3 immunization coverage among 1-year-olds (%),1015,<12 months
AFR0126,Proportion of population with primary reliance on clean fuels (%) -[SDG 7.1.2],11,Rural
AFR0126,Proportion of population with primary reliance on clean fuels (%) -[SDG 7.1.2],12,Urban
AFR0126,Proportion of population with primary reliance on clean fuels (%) -[SDG 7.1.2],28,Both sexes (male and female)
AFR0127,Domestic general government health expenditure as percentage of GGE (%) - [SDG 1.a.2],999,Not Applicable
AFR0128,UHC - Coverage of essential health services,28,Both sexes (male and female)
AFR0128,UHC - Coverage of essential health services,999,Not Applicable
AFR0129,Mortality attributable to joint effects of household and ambient air pollution,8,Male
AFR0129,Mortality attributable to joint effects of household and ambient air pollution,9,Female
AFR0129,Mortality attributable to joint effects of household and ambient air pollution,29,Total
AFR0130,Total fertility rate,9,Female
AFR0130,Total fertility rate,11,Rural
AFR0130,Total fertility rate,12,Urban
AFR0130,Total fertility rate,29,Total
AFR0130,Total fertility rate,66,Female (15-49 years)
AFR0130,Total fertility rate,107,Female (10-14 years)
AFR0130,Total fertility rate,109,Female (15-19 years)
AFR0131,Malaria parasite prevalence among children aged 6-59 months,29,Total
AFR0131,Malaria parasite prevalence among children aged 6-59 months,70,0-4 years
AFR0132,Mortality rate attributed to household and ambient air pollution [SDG 3.9.1],28,Both sexes (male and female)
AFR0133,Proportion of the target population covered by all vaccines included in their national programme [SDG 3.b.1],28,Both sexes (male and female)
AFR0134,Total net official development assistance to medical research and basic health sectors [SDG 3.b.2],999,Not Applicable
AFR0135,Percentage of pregnant women that made four or more ANC visits,9,Female
AFR0135,Percentage of pregnant women that made four or more ANC visits,11,Rural
AFR0135,Percentage of pregnant women that made four or more ANC visits,12,Urban
AFR0135,Percentage of pregnant women that made four or more ANC visits,23,Fifth Quintile
AFR0135,Percentage of pregnant women that made four or more ANC visits,42,Female (15+ years)
AFR0135,Percentage of pregnant women that made four or more ANC visits,66,Female (15-49 years)
AFR0136,Percentage of women that made their first ANC visit during the first trimester (first 12 weeks of pregnancy),9,Female
AFR0136,Percentage of women that made their first ANC visit during the first trimester (first 12 weeks of pregnancy),11,Rural
AFR0136,Percentage of women that made their first ANC visit during the first trimester (first 12 weeks of pregnancy),12,Urban
AFR0136,Percentage of women that made their first ANC visit during the first trimester (first 12 weeks of pregnancy),29,Total
AFR0136,Percentage of women that made their first ANC visit during the first trimester (first 12 weeks of pregnancy),66,Female (15-49 years)
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],2,Infants (0-11 Months)
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],11,Rural
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],12,Urban
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],14,No education
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],15,Primary Education
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],19,First Quintile
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],20,Second Quintile
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],21,Third Quintile
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],22,Fourth Quintile
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],23,Fifth Quintile
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],28,Both sexes (male and female)
AFR0137,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1],68,Secondary or Higher Education
AFR0140,Number of road traffic injuries,8,Male
AFR0140,Number of road traffic injuries,9,Female
AFR0140,Number of road traffic injuries,28,Both sexes (male and female)
AFR0140,Number of road traffic injuries,29,Total
AFR0141,Burden due to top 10 outpatient diagnose,28,Both sexes (male and female)
AFR0143,Population screened for diabetes,8,Male
AFR0143,Population screened for diabetes,28,Both sexes (male and female)
AFR0143,Population screened for diabetes,66,Female (15-49 years)
AFR0144,Population screened for cardiovascular diseases,8,Male
AFR0144,Population screened for cardiovascular diseases,28,Both sexes (male and female)
AFR0144,Population screened for cardiovascular diseases,66,Female (15-49 years)
AFR0147,Primary care facilities with capacity to provide essential health services,29,Total
AFR0147,Primary care facilities with capacity to provide essential health services,999,Not Applicable
AFR0148,Hospitals with capacity to provide their essential health services,29,Total
AFR0148,Hospitals with capacity to provide their essential health services,999,Not Applicable
AFR0149,Primary care facilities with capacity to provide basic surgical care,999,Not Applicable
AFR0150,Hospitals with capacity to provide comprehensive surgical care,999,Not Applicable
AFR0151,Primary care facilities with capacity to provide BEMONC services,999,Not Applicable
AFR0152,Hospitals with capacity to provide CEmONC services,29,Total
AFR0152,Hospitals with capacity to provide CEmONC services,999,Not Applicable
AFR0153,Coverage (%) - All Social Assistance,999,Not Applicable
AFR0154,Prevalence of stunting in children under 5 u (%),3,Under Fives ( 0-4 Years)
AFR0154,Prevalence of stunting in children under 5 u (%),11,Rural
AFR0154,Prevalence of stunting in children under 5 u (%),12,Urban
AFR0154,Prevalence of stunting in children under 5 u (%),14,No education
AFR0154,Prevalence of stunting in children under 5 u (%),15,Primary Education
AFR0154,Prevalence of stunting in children under 5 u (%),19,First Quintile
AFR0154,Prevalence of stunting in children under 5 u (%),20,Second Quintile
AFR0154,Prevalence of stunting in children under 5 u (%),21,Third Quintile
AFR0154,Prevalence of stunting in children under 5 u (%),22,Fourth Quintile
AFR0154,Prevalence of stunting in children under 5 u (%),23,Fifth Quintile
AFR0154,Prevalence of stunting in children under 5 u (%),28,Both sexes (male and female)
AFR0154,Prevalence of stunting in children under 5 u (%),29,Total
AFR0154,Prevalence of stunting in children under 5 u (%),68,Secondary or Higher Education
AFR0155,Prevalence of wasting in children under 5 u (%),3,Under Fives ( 0-4 Years)
AFR0155,Prevalence of wasting in children under 5 u (%),11,Rural
AFR0155,Prevalence of wasting in children under 5 u (%),12,Urban
AFR0155,Prevalence of wasting in children under 5 u (%),14,No education
AFR0155,Prevalence of wasting in children under 5 u (%),15,Primary Education
AFR0155,Prevalence of wasting in children under 5 u (%),19,First Quintile
AFR0155,Prevalence of wasting in children under 5 u (%),20,Second Quintile
AFR0155,Prevalence of wasting in children under 5 u (%),21,Third Quintile
AFR0155,Prevalence of wasting in children under 5 u (%),22,Fourth Quintile
AFR0155,Prevalence of wasting in children under 5 u (%),23,Fifth Quintile
AFR0155,Prevalence of wasting in children under 5 u (%),28,Both sexes (male and female)
AFR0155,Prevalence of wasting in children under 5 u (%),68,Secondary or Higher Education
AFR0156,Prevalence of overweight in children under 5 u (%),28,Both sexes (male and female)
AFR0157,"Primary education, duration (years)",999,Not Applicable
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",8,Male
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",9,Female
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",11,Rural
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",28,Both sexes (male and female)
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",29,Total
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",72,10-14 years
AFR0158,"Lower secondary completion rate, total (% of relevant age group)",1049,12-14 years
AFR0159,"Primary completion rate, total (% of relevant age group)",8,Male
AFR0159,"Primary completion rate, total (% of relevant age group)",9,Female
AFR0159,"Primary completion rate, total (% of relevant age group)",11,Rural
AFR0159,"Primary completion rate, total (% of relevant age group)",28,Both sexes (male and female)
AFR0159,"Primary completion rate, total (% of relevant age group)",71,5-9 years
AFR0159,"Primary completion rate, total (% of relevant age group)",1039,5-14 years
AFR0159,"Primary completion rate, total (% of relevant age group)",1048,6-11 years
AFR0160,School dropout rate,8,Male
AFR0160,School dropout rate,9,Female
AFR0160,School dropout rate,15,Primary Education
AFR0160,School dropout rate,28,Both sexes (male and female)
AFR0160,School dropout rate,69,Secondary Education
AFR0160,School dropout rate,1039,5-14 years
AFR0160,School dropout rate,1049,12-14 years
AFR0161,School enrollment rate,28,Both sexes (male and female)
AFR0162,Treatment coverage for alcohol and drug dependence [SDG 3.5.1],28,Both sexes (male and female)
AFR0164,Coverage of preventive chemotherapy for selected neglected tropical diseases,28,Both sexes (male and female)
AFR0165,Indoor residual spraying (IRS) coverage,28,Both sexes (male and female)
AFR0166,Treatment of confirmed malaria cases,29,Total
AFR0167,Use of insecticide treated nets (ITNs),28,Both sexes (male and female)
AFR0167,Use of insecticide treated nets (ITNs),29,Total
AFR0168,Intermittent preventive therapy for malaria during pregnancy (IPTp),9,Female
AFR0168,Intermittent preventive therapy for malaria during pregnancy (IPTp),29,Total
AFR0168,Intermittent preventive therapy for malaria during pregnancy (IPTp),66,Female (15-49 years)
AFR0169,HIV-positive new and relapse TB patients on ART during TB treatment,28,Both sexes (male and female)
AFR0169,HIV-positive new and relapse TB patients on ART during TB treatment,29,Total
AFR0170,TB preventive therapy for HIV-positive people newly enrolled in HIV care,8,Male
AFR0170,TB preventive therapy for HIV-positive people newly enrolled in HIV care,9,Female
AFR0170,TB preventive therapy for HIV-positive people newly enrolled in HIV care,28,Both sexes (male and female)
AFR0170,TB preventive therapy for HIV-positive people newly enrolled in HIV care,29,Total
AFR0170,TB preventive therapy for HIV-positive people newly enrolled in HIV care,42,Female (15+ years)
AFR0171,HIV test results for registered new and relapse TB patients,28,Both sexes (male and female)
AFR0171,HIV test results for registered new and relapse TB patients,29,Total
AFR0172,Treatment coverage for drug-resistant TB,29,Total
AFR0173,TB treatment coverage,28,Both sexes (male and female)
AFR0173,TB treatment coverage,29,Total
AFR0174,Drug susceptibility testing coverage for TB patients,29,Total
AFR0175,Coverage of treatment for latent TB infection (LTBI),28,Both sexes (male and female)
AFR0175,Coverage of treatment for latent TB infection (LTBI),29,Total
AFR0176,TB case detection rate,28,Both sexes (male and female)
AFR0176,TB case detection rate,29,Total
AFR0178,Viral load suppression,28,Both sexes (male and female)
AFR0178,Viral load suppression,29,Total
AFR0178,Viral load suppression,42,Female (15+ years)
AFR0178,Viral load suppression,45,Male (15+ years)
AFR0179,Coverage of antiretroviral therapy (ART) (also effective ART treatment coverage),28,Both sexes (male and female)
AFR0179,Coverage of antiretroviral therapy (ART) (also effective ART treatment coverage),29,Total
AFR0180,Coverage of prevention of mother-to-child transmission (also effective PMTCT coverage),9,Female
AFR0180,Coverage of prevention of mother-to-child transmission (also effective PMTCT coverage),29,Total
AFR0180,Coverage of prevention of mother-to-child transmission (also effective PMTCT coverage),42,Female (15+ years)
AFR0180,Coverage of prevention of mother-to-child transmission (also effective PMTCT coverage),66,Female (15-49 years)
AFR0181,People living with HIV who know their status,28,Both sexes (male and female)
AFR0181,People living with HIV who know their status,29,Total
AFR0182,Care seeking for children with fever,3,Under Fives ( 0-4 Years)
AFR0182,Care seeking for children with fever,8,Male
AFR0182,Care seeking for children with fever,9,Female
AFR0182,Care seeking for children with fever,11,Rural
AFR0182,Care seeking for children with fever,12,Urban
AFR0182,Care seeking for children with fever,28,Both sexes (male and female)
AFR0182,Care seeking for children with fever,1018,12-23 months
AFR0182,Care seeking for children with fever,1019,24-35 months
AFR0182,Care seeking for children with fever,1020,36-47 months
AFR0182,Care seeking for children with fever,1021,48-59 months
AFR0182,Care seeking for children with fever,1040,Less 6 months
AFR0182,Care seeking for children with fever,1055,6-11 months
AFR0182,Care seeking for children with fever,1062,24-35 months
AFR0182,Care seeking for children with fever,1064,48-59 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,3,Under Fives ( 0-4 Years)
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,8,Male
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,9,Female
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,11,Rural
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,12,Urban
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,29,Total
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1018,12-23 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1019,24-35 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1020,36-47 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1021,48-59 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1040,Less 6 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1055,6-11 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1062,24-35 months
AFR0183,Care seeking for children with symptoms of diarrhoea treatment,1064,48-59 months
AFR0184,Care-seeking for children with symptoms of pneumonia,3,Under Fives ( 0-4 Years)
AFR0184,Care-seeking for children with symptoms of pneumonia,8,Male
AFR0184,Care-seeking for children with symptoms of pneumonia,9,Female
AFR0184,Care-seeking for children with symptoms of pneumonia,11,Rural
AFR0184,Care-seeking for children with symptoms of pneumonia,12,Urban
AFR0184,Care-seeking for children with symptoms of pneumonia,28,Both sexes (male and female)
AFR0184,Care-seeking for children with symptoms of pneumonia,1018,12-23 months
AFR0184,Care-seeking for children with symptoms of pneumonia,1019,24-35 months
AFR0184,Care-seeking for children with symptoms of pneumonia,1020,36-47 months
AFR0184,Care-seeking for children with symptoms of pneumonia,1021,48-59 months
AFR0184,Care-seeking for children with symptoms of pneumonia,1040,Less 6 months
AFR0184,Care-seeking for children with symptoms of pneumonia,1055,6-11 months
AFR0185,Vitamin A supplementation coverage,4,Children (5-9 Years)
AFR0185,Vitamin A supplementation coverage,28,Both sexes (male and female)
AFR0185,Vitamin A supplementation coverage,29,Total
AFR0185,Vitamin A supplementation coverage,1026,24-59 months
AFR0186,Pneumococcal vaccination coverage,28,Both sexes (male and female)
AFR0186,Pneumococcal vaccination coverage,29,Total
AFR0186,Pneumococcal vaccination coverage,1015,<12 months
AFR0187,Immunization coverage against Rotavirus vaccine,2,Infants (0-11 Months)
AFR0187,Immunization coverage against Rotavirus vaccine,3,Under Fives ( 0-4 Years)
AFR0187,Immunization coverage against Rotavirus vaccine,28,Both sexes (male and female)
AFR0187,Immunization coverage against Rotavirus vaccine,1015,<12 months
AFR0187,Immunization coverage against Rotavirus vaccine,1025,18 months
AFR0188,Immunization coverage against HPV,9,Female
AFR0189,Immunization coverage against Tetanus,28,Both sexes (male and female)
AFR0189,Immunization coverage against Tetanus,29,Total
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,2,Infants (0-11 Months)
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,11,Rural
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,12,Urban
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,14,No education
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,15,Primary Education
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,19,First Quintile
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,20,Second Quintile
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,21,Third Quintile
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,22,Fourth Quintile
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,23,Fifth Quintile
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,28,Both sexes (male and female)
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,29,Total
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,68,Secondary or Higher Education
AFR0190,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Measles,1027,9 months
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,2,Infants (0-11 Months)
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,11,Rural
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,12,Urban
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,14,No education
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,15,Primary Education
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,19,First Quintile
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,20,Second Quintile
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,21,Third Quintile
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,22,Fourth Quintile
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,23,Fifth Quintile
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,28,Both sexes (male and female)
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,68,Secondary or Higher Education
AFR0191,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 3,1015,<12 months
AFR0192,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 2,2,Infants (0-11 Months)
AFR0192,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 2,28,Both sexes (male and female)
AFR0192,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 2,1015,<12 months
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,2,Infants (0-11 Months)
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,11,Rural
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,12,Urban
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,14,No education
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,15,Primary Education
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,19,First Quintile
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,20,Second Quintile
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,21,Third Quintile
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,22,Fourth Quintile
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,23,Fifth Quintile
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,28,Both sexes (male and female)
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,68,Secondary or Higher Education
AFR0193,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Penta 1,1015,<12 months
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,2,Infants (0-11 Months)
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,11,Rural
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,12,Urban
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,14,No education
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,15,Primary Education
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,19,First Quintile
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,20,Second Quintile
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,21,Third Quintile
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,22,Fourth Quintile
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,23,Fifth Quintile
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,28,Both sexes (male and female)
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,29,Total
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,68,Secondary or Higher Education
AFR0194,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 3,1015,<12 months
AFR0195,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 2,2,Infants (0-11 Months)
AFR0195,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 2,1015,<12 months
AFR0196,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 1,2,Infants (0-11 Months)
AFR0196,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 1,29,Total
AFR0196,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - Polio 1,1015,<12 months
AFR0197,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - BCG,2,Infants (0-11 Months)
AFR0197,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - BCG,28,Both sexes (male and female)
AFR0197,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - BCG,29,Total
AFR0197,Immunization coverage rate by vaccine for each vaccine in the national schedule [SDG 3.b.1] - BCG,1015,<12 months
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,1,Neonate (0-28 Days)
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,3,Under Fives ( 0-4 Years)
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,11,Rural
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,12,Urban
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,14,No education
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,19,First Quintile
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,20,Second Quintile
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,22,Fourth Quintile
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,23,Fifth Quintile
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,29,Total
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,68,Secondary or Higher Education
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,1023,Middle
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,1051,<20years
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,1056,20-34 years
AFR0199,Postnatal care coverage: Percentage of newborn babies who have postnatal care contact within two days following birth,1057,35-49 years
AFR0200,Institutional deliveries,9,Female
AFR0200,Institutional deliveries,11,Rural
AFR0200,Institutional deliveries,12,Urban
AFR0200,Institutional deliveries,19,First Quintile
AFR0200,Institutional deliveries,20,Second Quintile
AFR0200,Institutional deliveries,22,Fourth Quintile
AFR0200,Institutional deliveries,23,Fifth Quintile
AFR0200,Institutional deliveries,29,Total
AFR0200,Institutional deliveries,66,Female (15-49 years)
AFR0200,Institutional deliveries,1023,Middle
AFR0200,Institutional deliveries,1051,<20years
AFR0200,Institutional deliveries,1056,20-34 years
AFR0200,Institutional deliveries,1057,35-49 years
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],5,Adolescents (10-19 Years)
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],9,Female
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],11,Rural
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],12,Urban
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],14,No education
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],15,Primary Education
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],19,First Quintile
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],20,Second Quintile
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],21,Third Quintile
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],22,Fourth Quintile
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],23,Fifth Quintile
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],26,25-64 years
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],27,65+ years
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],28,Both sexes (male and female)
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],29,Total
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],66,Female (15-49 years)
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],68,Secondary or Higher Education
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],69,Secondary Education
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],1051,<20years
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],1056,20-34 years
AFR0201,Proportion of births attended by skilled health personnel [SDG 3.1.2],1057,35-49 years
AFR0202,Timing of first ANC visit,9,Female
AFR0202,Timing of first ANC visit,11,Rural
AFR0202,Timing of first ANC visit,12,Urban
AFR0202,Timing of first ANC visit,29,Total
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),9,Female
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),11,Rural
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),12,Urban
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),19,First Quintile
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),20,Second Quintile
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),22,Fourth Quintile
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),23,Fifth Quintile
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),29,Total
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),66,Female (15-49 years)
AFR0203,Percentage of pregnant women that made four ANC visits (Fourth ANC visit),1023,Middle
AFR0204,Percentage of pregnant women that made at least three ANC visits (Third ANC visit),66,Female (15-49 years)
AFR0205,Percentage of pregnant women that made at least two ANC visits (second ANC visit),11,Rural
AFR0205,Percentage of pregnant women that made at least two ANC visits (second ANC visit),12,Urban
AFR0205,Percentage of pregnant women that made at least two ANC visits (second ANC visit),29,Total
AFR0205,Percentage of pregnant women that made at least two ANC visits (second ANC visit),66,Female (15-49 years)
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),9,Female
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),11,Rural
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),12,Urban
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),19,First Quintile
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),20,Second Quintile
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),22,Fourth Quintile
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),23,Fifth Quintile
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),29,Total
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),66,Female (15-49 years)
AFR0206,Percentage of pregnant women that made at least one ANC visit (first ANC visit),1023,Middle
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],9,Female
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],11,Rural
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],12,Urban
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],14,No education
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],15,Primary Education
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],19,First Quintile
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],20,Second Quintile
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],21,Third Quintile
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],22,Fourth Quintile
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],23,Fifth Quintile
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],29,Total
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],66,Female (15-49 years)
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],68,Secondary or Higher Education
AFR0207,Demand for family planning satisfied with modern methods [SDG 3.7.1],69,Secondary Education
AFR0208,Contraceptive prevalence rate,9,Female
AFR0208,Contraceptive prevalence rate,11,Rural
AFR0208,Contraceptive prevalence rate,12,Urban
AFR0208,Contraceptive prevalence rate,29,Total
AFR0208,Contraceptive prevalence rate,66,Female (15-49 years)
AFR0208,Contraceptive prevalence rate,129,Married women
AFR0212,Effective hypertensive treatment coverage,29,Total
AFR0213,Effective PMTCT coverage,9,Female
AFR0214,ART retention rate,28,Both sexes (male and female)
AFR0216,TB treatment success rate,28,Both sexes (male and female)
AFR0216,TB treatment success rate,29,Total
AFR0217,Fresh stillbirth rate,2,Infants (0-11 Months)
AFR0217,Fresh stillbirth rate,29,Total
AFR0218,Maternal death review coverage (%),9,Female
AFR0219,Institutional maternal mortality ratio (per 100 000 deliveries),29,Total
AFR0219,Institutional maternal mortality ratio (per 100 000 deliveries),66,Female (15-49 years)
AFR0220,Readiness for blood transfusion,29,Total
AFR0220,Readiness for blood transfusion,999,Not Applicable
AFR0221,Readiness for basic surgical care,29,Total
AFR0221,Readiness for basic surgical care,999,Not Applicable
AFR0222,Readiness for adolescent health services,29,Total
AFR0222,Readiness for adolescent health services,999,Not Applicable
AFR0223,TB treatment completion rate,29,Total
AFR0224,Skilled birth attendance - postnatal care dropout,66,Female (15-49 years)
AFR0225,ANC dropout rate (ANC1-ANC 4),66,Female (15-49 years)
AFR0226,DTP dropout rate (DTP1 -DPT3),2,Infants (0-11 Months)
AFR0226,DTP dropout rate (DTP1 -DPT3),28,Both sexes (male and female)
AFR0226,DTP dropout rate (DTP1 -DPT3),29,Total
AFR0227,Tuberculosis diagnosis and treatment,29,Total
AFR0229,Service availability index (%) (high-level indicator),999,Not Applicable
AFR0231,Hospital bed density (per 10 000 population),999,Not Applicable
AFR0232,"Health facility density and distribution (per 10,000 population)",29,Total
AFR0232,"Health facility density and distribution (per 10,000 population)",999,Not Applicable
AFR0234,Presence and quality of national M&E plan / HIS strategic plan / digital health strategy,29,Total
AFR0234,Presence and quality of national M&E plan / HIS strategic plan / digital health strategy,999,Not Applicable
AFR0235,Public access to data/open data,999,Not Applicable
AFR0236,Health worker density and distribution [SDG 3.c.1],29,Total
AFR0236,Health worker density and distribution [SDG 3.c.1],32,Dentistry
AFR0236,Health worker density and distribution [SDG 3.c.1],999,Not Applicable
AFR0237,Functional system of health accounts based on international standards,29,Total
AFR0237,Functional system of health accounts based on international standards,999,Not Applicable
AFR0239,Functional facility/community/patient reporting system in place based on key criteria,999,Not Applicable
AFR0240,Annual statistic for selected indicators derived from facility data,999,Not Applicable
AFR0241,Functional system to generate cause-of-death statistics,999,Not Applicable
AFR0242,Percentage of deaths occurring with cause of death according to international standards,65,Both sexes (15-49 yeras)
AFR0245,Completeness of birth registration (%),28,Both sexes (male and female)
AFR0245,Completeness of birth registration (%),999,Not Applicable
AFR0247,Existence of a system of regular & comprehensive population health surveys that meets international standards,999,Not Applicable
AFR0248,Latest data to monitor the health- related SDGs /UHC are available as per recommended schedule,999,Not Applicable
AFR0249,Rational use of health products,999,Not Applicable
AFR0249,Rational use of health products,1028,Encounters with an antibiotic prescribed
AFR0249,Rational use of health products,1029,Encounters with an injection prescribed
AFR0249,Rational use of health products,1030,Encounters with medicines prescribed by generic names
AFR0249,Rational use of health products,1032,Average number of medicines per encounter
AFR0250,Existence of national health sector policy/strategy/plan,999,Not Applicable
AFR0251,International Health Regulations (IHR) core capacities index - [SDG 3.d.1],28,Both sexes (male and female)
AFR0251,International Health Regulations (IHR) core capacities index - [SDG 3.d.1],29,Total
AFR0251,International Health Regulations (IHR) core capacities index - [SDG 3.d.1],999,Not Applicable
AFR0253,"Pharmacists (per 10,000 population)",28,Both sexes (male and female)
AFR0255,Access to a core set of relevant essential medicines [SDG 3.b.3],29,Total
AFR0257,Out-of-Pocket expenditure (OOP) per capita in PPP int$,28,Both sexes (male and female)
AFR0257,Out-of-Pocket expenditure (OOP) per capita in PPP int$,999,Not Applicable
AFR0258,Out-of-Pocket expenditure (OOP) per capita in US$,109,Female (15-19 years)
AFR0258,Out-of-Pocket expenditure (OOP) per capita in US$,999,Not Applicable
AFR0259,Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%),999,Not Applicable
AFR0260,Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%),999,Not Applicable
AFR0261,Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%),999,Not Applicable
AFR0262,Current health expenditure (CHE) per capita in PPP int$,999,Not Applicable
AFR0263,Current health expenditure (CHE) per capita in US$,999,Not Applicable
AFR0266,Total Health Expenditure (THE) per Capita in Int$ (Purchasing Power Parity),999,Not Applicable
AFR0267,Total Health Expenditure (THE) per Capita in US$,999,Not Applicable
AFR0268,Out-of-pocket (OOPS) as % of Current Health Expenditure (CHE),109,Female (15-19 years)
AFR0268,Out-of-pocket (OOPS) as % of Current Health Expenditure (CHE),999,Not Applicable
AFR0269,Out of Pocket Expenditure (OOPS) as % of Total Health Expenditure (THE),999,Not Applicable
AFR0270,Social Health Insurance (SHI) as % of Current Health Expenditure (CHE),28,Both sexes (male and female)
AFR0271,External Resources on Health as % of Total Health Expenditure (THE),999,Not Applicable
AFR0272,General Government Health Expenditure (GGHE) as % of Total health expenditure (GGE),999,Not Applicable
AFR0274,Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE),999,Not Applicable
AFR0277,Services management,999,Not Applicable
AFR0278,Supervision mechanisms for service delivery,999,Not Applicable
AFR0279,Health facility density and distribution,999,Not Applicable
AFR0280,Health management and support workers density (per 1000 population),28,Both sexes (male and female)
AFR0280,Health management and support workers density (per 1000 population),999,Not Applicable
AFR0281,Community health workers density (per 1000 population),28,Both sexes (male and female)
AFR0281,Community health workers density (per 1000 population),999,Not Applicable
AFR0282,Environmental and public health workers density (per 1000 population),28,Both sexes (male and female)
AFR0282,Environmental and public health workers density (per 1000 population),999,Not Applicable
AFR0283,Laboratory health workers density (per 1000 population),28,Both sexes (male and female)
AFR0283,Laboratory health workers density (per 1000 population),999,Not Applicable
AFR0284,Pharmaceutical personnel density (per 1000 population),28,Both sexes (male and female)
AFR0284,Pharmaceutical personnel density (per 1000 population),999,Not Applicable
AFR0285,Dentistry personnel density (per 1000 population),28,Both sexes (male and female)
AFR0286,Nursing and midwifery personnel density (per 1000 population),28,Both sexes (male and female)
AFR0286,Nursing and midwifery personnel density (per 1000 population),29,Total
AFR0286,Nursing and midwifery personnel density (per 1000 population),999,Not Applicable
AFR0287,Physicians density (per 1000 population),28,Both sexes (male and female)
AFR0287,Physicians density (per 1000 population),999,Not Applicable
AFR0288,"Core health workforce density (per 1,000 population) (doctors, nurses/midwives, and clinical officers/physician assistants)",999,Not Applicable
AFR0291,Population using safely managed sanitation services [SDG 6.2.1a/6.2.1b],11,Rural
AFR0291,Population using safely managed sanitation services [SDG 6.2.1a/6.2.1b],12,Urban
AFR0291,Population using safely managed sanitation services [SDG 6.2.1a/6.2.1b],28,Both sexes (male and female)
AFR0291,Population using safely managed sanitation services [SDG 6.2.1a/6.2.1b],29,Total
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],8,Male
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],9,Female
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],11,Rural
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],12,Urban
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],28,Both sexes (male and female)
AFR0292,Population using safely managed drinking-water services [SDG 6.1.1],29,Total
AFR0293,Adolescent birth rate [SDG 3.7.2],5,Adolescents (10-19 Years)
AFR0293,Adolescent birth rate [SDG 3.7.2],9,Female
AFR0293,Adolescent birth rate [SDG 3.7.2],93,Male (25-29 years)
AFR0294,Social security funds as % of General government health expenditure (GGHE),999,Not Applicable
AFR0295,Sexual violence against children [SDG 16.2.3],8,Male
AFR0295,Sexual violence against children [SDG 16.2.3],9,Female
AFR0296,Non-partner sexual violence prevalence [SDG 5.2.2],66,Female (15-49 years)
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],9,Female
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],11,Rural
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],12,Urban
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],28,Both sexes (male and female)
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],29,Total
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],109,Female (15-19 years)
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],110,Female (20-24 years)
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],111,Female (25-29 years)
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],1053,30-39 years
AFR0297,Intimate partner violence prevalence [SDG 5.2.1],1054,40-49 years
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],9,Female
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],11,Rural
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],12,Urban
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],66,Female (15-49 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],109,Female (15-19 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],110,Female (20-24 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],111,Female (25-29 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],112,Female (30-34 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],113,Female (35-39 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],114,Female (40-44 years)
AFR0298,Prevalence of female genital mutilation/cutting [SDG 5.3.2],115,Female (45-49 years)
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",9,Female
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",66,Female (15-49 years)
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",73,15-19 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",74,20-24 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",75,25-29 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",76,30-34 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",77,35-39 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",78,40-44 years
AFR0299,"Prevalence of anaemia in women aged 15-49, by age and pregnancy status",79,45-49 years
AFR0300,Anaemia prevalence in children,3,Under Fives ( 0-4 Years)
AFR0300,Anaemia prevalence in children,8,Male
AFR0300,Anaemia prevalence in children,9,Female
AFR0300,Anaemia prevalence in children,11,Rural
AFR0300,Anaemia prevalence in children,12,Urban
AFR0300,Anaemia prevalence in children,28,Both sexes (male and female)
AFR0300,Anaemia prevalence in children,1042,>5 years
AFR0300,Anaemia prevalence in children,1058,6-8 months
AFR0300,Anaemia prevalence in children,1059,9-11 months
AFR0300,Anaemia prevalence in children,1060,12-17 months
AFR0300,Anaemia prevalence in children,1061,18-23 months
AFR0300,Anaemia prevalence in children,1062,24-35 months
AFR0300,Anaemia prevalence in children,1063,36-47 months
AFR0300,Anaemia prevalence in children,1065,48-59 months
AFR0301,Children aged under 5 years who are overweight [SDG 2.2.2],28,Both sexes (male and female)
AFR0302,Children under 5 years who are wasted [SDG 2.2.2],8,Male
AFR0302,Children under 5 years who are wasted [SDG 2.2.2],9,Female
AFR0302,Children under 5 years who are wasted [SDG 2.2.2],11,Rural
AFR0302,Children under 5 years who are wasted [SDG 2.2.2],12,Urban
AFR0302,Children under 5 years who are wasted [SDG 2.2.2],28,Both sexes (male and female)
AFR0303,Children under 5 years who are stunted [SDG 2.2.1],8,Male
AFR0303,Children under 5 years who are stunted [SDG 2.2.1],9,Female
AFR0303,Children under 5 years who are stunted [SDG 2.2.1],11,Rural
AFR0303,Children under 5 years who are stunted [SDG 2.2.1],12,Urban
AFR0303,Children under 5 years who are stunted [SDG 2.2.1],28,Both sexes (male and female)
AFR0304,Incidence of low birth weight among newborns,11,Rural
AFR0304,Incidence of low birth weight among newborns,12,Urban
AFR0304,Incidence of low birth weight among newborns,28,Both sexes (male and female)
AFR0304,Incidence of low birth weight among newborns,1004,Both sexes (0-28 Days)
AFR0305,Early initiation of breastfeeding (%),1,Neonate (0-28 Days)
AFR0305,Early initiation of breastfeeding (%),8,Male
AFR0305,Early initiation of breastfeeding (%),9,Female
AFR0305,Early initiation of breastfeeding (%),11,Rural
AFR0305,Early initiation of breastfeeding (%),12,Urban
AFR0305,Early initiation of breastfeeding (%),28,Both sexes (male and female)
AFR0305,Early initiation of breastfeeding (%),29,Total
AFR0305,Early initiation of breastfeeding (%),1004,Both sexes (0-28 Days)
AFR0306,Prevalence of exclusive breastfeeding in infants aged six months or less (Exclusive BF),28,Both sexes (male and female)
AFR0306,Prevalence of exclusive breastfeeding in infants aged six months or less (Exclusive BF),1005,Infants (0-6 Months)
AFR0306,Prevalence of exclusive breastfeeding in infants aged six months or less (Exclusive BF),1040,Less 6 months
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),8,Male
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),9,Female
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),28,Both sexes (male and female)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),29,Total
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),91,Male ((15-19 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),92,Male (20-24 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),93,Male (25-29 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),94,Male (30-34 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),95,Male (35-39 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),96,Male (40-44 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),97,Male (45-49 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),109,Female (15-19 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),110,Female (20-24 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),111,Female (25-29 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),112,Female (30-34 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),113,Female (35-39 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),114,Female (40-44 years)
AFR0307,Tobacco use among persons aged 15+ years - [SDG 3.a.1] (Also: adolescents),115,Female (45-49 years)
AFR0308,Age-standardized prevalence of insufficiently physically active persons aged 18+ years,8,Male
AFR0308,Age-standardized prevalence of insufficiently physically active persons aged 18+ years,9,Female
AFR0308,Age-standardized prevalence of insufficiently physically active persons aged 18+ years,28,Both sexes (male and female)
AFR0308,Age-standardized prevalence of insufficiently physically active persons aged 18+ years,29,Total
AFR0310,Total alcohol per capita (age 15+ years) consumption [SDG 3.5.2],8,Male
AFR0310,Total alcohol per capita (age 15+ years) consumption [SDG 3.5.2],9,Female
AFR0310,Total alcohol per capita (age 15+ years) consumption [SDG 3.5.2],28,Both sexes (male and female)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,8,Male
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,9,Female
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,28,Both sexes (male and female)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,29,Total
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,41,Both sexes (18+ years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,43,Female (18+ years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,44,Male (18+ years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,91,Male ((15-19 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,92,Male (20-24 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,93,Male (25-29 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,94,Male (30-34 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,95,Male (35-39 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,96,Male (40-44 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,97,Male (45-49 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,109,Female (15-19 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,110,Female (20-24 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,111,Female (25-29 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,112,Female (30-34 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,113,Female (35-39 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,114,Female (40-44 years)
AFR0311,Age-standardized prevalence of raised blood pressure among persons aged 18+ years,115,Female (45-49 years)
AFR0312,Prevalence of raised blood cholesterol,29,Total
AFR0313,Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years or on medication for raised blood glucose,8,Male
AFR0313,Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years or on medication for raised blood glucose,9,Female
AFR0313,Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years or on medication for raised blood glucose,28,Both sexes (male and female)
AFR0313,Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years or on medication for raised blood glucose,29,Total
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,9,Female
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,11,Rural
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,12,Urban
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,14,No education
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,15,Primary Education
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,19,First Quintile
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,20,Second Quintile
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,21,Third Quintile
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,22,Fourth Quintile
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,23,Fifth Quintile
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,29,Total
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,66,Female (15-49 years)
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,68,Secondary or Higher Education
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,69,Secondary Education
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,1023,Middle
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,1051,<20years
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,1056,20-34 years
AFR0314,Percentage of women who received postnatal (postpartum care) within two days of child birth,1057,35-49 years
AFR0315,Early marriage,9,Female
AFR0319,Prevalence chronic obstructive pulmonary diseases,8,Male
AFR0319,Prevalence chronic obstructive pulmonary diseases,9,Female
AFR0319,Prevalence chronic obstructive pulmonary diseases,28,Both sexes (male and female)
AFR0319,Prevalence chronic obstructive pulmonary diseases,29,Total
AFR0320,Incidence of stroke/cardiovascular disease,29,Total
AFR0321,Number of cancer cases (all cause),29,Total
AFR0324,New cases of vaccine-preventable diseases,28,Both sexes (male and female)
AFR0324,New cases of vaccine-preventable diseases,46,Measles
AFR0324,New cases of vaccine-preventable diseases,47,Mumps
AFR0324,New cases of vaccine-preventable diseases,48,Neonatal tetanus
AFR0324,New cases of vaccine-preventable diseases,49,Non-neonatal tetanus
AFR0324,New cases of vaccine-preventable diseases,50,Pertussis
AFR0324,New cases of vaccine-preventable diseases,51,Polio
AFR0324,New cases of vaccine-preventable diseases,52,Rubella
AFR0324,New cases of vaccine-preventable diseases,53,Yellow fever
AFR0324,New cases of vaccine-preventable diseases,54,Congenital Rubella Syndrome
AFR0324,New cases of vaccine-preventable diseases,55,Diphteria
AFR0324,New cases of vaccine-preventable diseases,56,Japanese encephalitis
AFR0324,New cases of vaccine-preventable diseases,57,Measles
AFR0324,New cases of vaccine-preventable diseases,58,Mumps
AFR0324,New cases of vaccine-preventable diseases,59,Neonatal tetanus
AFR0324,New cases of vaccine-preventable diseases,60,Non-neonatal tetanus
AFR0324,New cases of vaccine-preventable diseases,61,Pertussis
AFR0325,Hepatitis B incidence per 100 000 population [SDG 3.3.4],28,Both sexes (male and female)
AFR0325,Hepatitis B incidence per 100 000 population [SDG 3.3.4],29,Total
AFR0326,Hepatitis B surface antigen prevalence (%),28,Both sexes (male and female)
AFR0327,Number of people requiring interventions against neglected tropical diseases [SDG 3.3.5],28,Both sexes (male and female)
AFR0328,Congenital syphilis rate,28,Both sexes (male and female)
AFR0328,Congenital syphilis rate,66,Female (15-49 years)
AFR0330,Malaria prevalence rate,28,Both sexes (male and female)
AFR0330,Malaria prevalence rate,29,Total
AFR0330,Malaria prevalence rate,1050,6-59 months
AFR0331,Malaria incidence rate (per 1000 population at risk) [SDG 3.3.3],28,Both sexes (male and female)
AFR0331,Malaria incidence rate (per 1000 population at risk) [SDG 3.3.3],29,Total
AFR0332,"TB prevalence rate per 100,000 population per year",28,Both sexes (male and female)
AFR0332,"TB prevalence rate per 100,000 population per year",29,Total
AFR0333,Tuberculosis (TB) notification rate (per 100 000 population),28,Both sexes (male and female)
AFR0333,Tuberculosis (TB) notification rate (per 100 000 population),29,Total
AFR0334,TB incidence rate [SDG 3.3.2],28,Both sexes (male and female)
AFR0334,TB incidence rate [SDG 3.3.2],29,Total
AFR0335,Tuberculosis treatment success rate,28,Both sexes (male and female)
AFR0335,Tuberculosis treatment success rate,29,Total
AFR0335,Tuberculosis treatment success rate,109,Female (15-19 years)
AFR0339,ANC Coverage,9,Female
AFR0339,ANC Coverage,11,Rural
AFR0339,ANC Coverage,12,Urban
AFR0339,ANC Coverage,66,Female (15-49 years)
AFR0340,BCG - MCV drop out,2,Infants (0-11 Months)
AFR0341,TB treatment drop out,28,Both sexes (male and female)
AFR0346,Patient safety index score,999,Not Applicable
AFR0347,Gender development index score,28,Both sexes (male and female)
AFR0348,Total Health Expenditure (International US$),999,Not Applicable
AFR0349,Total Health Expenditure (constant US$),999,Not Applicable
AFR0350,Availability of basic equipment,29,Total
AFR0350,Availability of basic equipment,999,Not Applicable
AFR0351,Health infrastructure readiness,999,Not Applicable
AFR0352,Facilities with essential medicines out of stock in the past 3 months,999,Not Applicable
AFR0358,Diagnostics readiness,29,Total
AFR0358,Diagnostics readiness,999,Not Applicable
AFR0361,Primary care facilities readiness score,999,Not Applicable
AFR0362,Hospitals readiness score,999,Not Applicable
AFR0363,Facilities that received expected supervision visits in the past 6 months,999,Not Applicable
AFR0365,Sub national units with full complement of management staff (DHMTs),999,Not Applicable
AFR0366,Facilities with appropriate infection prevention,29,Total
AFR0366,Facilities with appropriate infection prevention,999,Not Applicable
AFR0368,Annual health summit held in past 12 months,999,Not Applicable
AFR0369,Sub national units (districts) with current operational plans,999,Not Applicable
AFR0373,Proportion of deaths with cause of death recorded,29,Total
AFR0376,Functionality of health observatory,999,Not Applicable
AFR0377,HIV prevalence among adults aged 15-49 years (%),8,Male
AFR0377,HIV prevalence among adults aged 15-49 years (%),9,Female
AFR0377,HIV prevalence among adults aged 15-49 years (%),11,Rural
AFR0377,HIV prevalence among adults aged 15-49 years (%),12,Urban
AFR0377,HIV prevalence among adults aged 15-49 years (%),14,No education
AFR0377,HIV prevalence among adults aged 15-49 years (%),15,Primary Education
AFR0377,HIV prevalence among adults aged 15-49 years (%),19,First Quintile
AFR0377,HIV prevalence among adults aged 15-49 years (%),20,Second Quintile
AFR0377,HIV prevalence among adults aged 15-49 years (%),21,Third Quintile
AFR0377,HIV prevalence among adults aged 15-49 years (%),22,Fourth Quintile
AFR0377,HIV prevalence among adults aged 15-49 years (%),23,Fifth Quintile
AFR0377,HIV prevalence among adults aged 15-49 years (%),28,Both sexes (male and female)
AFR0377,HIV prevalence among adults aged 15-49 years (%),29,Total
AFR0377,HIV prevalence among adults aged 15-49 years (%),65,Both sexes (15-49 yeras)
AFR0377,HIV prevalence among adults aged 15-49 years (%),67,Male (15-49 years)
AFR0377,HIV prevalence among adults aged 15-49 years (%),68,Secondary or Higher Education
AFR0378,Age-standardized prevalence of overweight and obesity in persons aged 18+ years,29,Total
AFR0379,Age-standardized prevalence of overweight in persons aged 18+ years,8,Male
AFR0379,Age-standardized prevalence of overweight in persons aged 18+ years,28,Both sexes (male and female)
AFR0379,Age-standardized prevalence of overweight in persons aged 18+ years,66,Female (15-49 years)
AFR0380,Access to electricity (% of population),8,Male
AFR0380,Access to electricity (% of population),9,Female
AFR0380,Access to electricity (% of population),11,Rural
AFR0380,Access to electricity (% of population),12,Urban
AFR0380,Access to electricity (% of population),28,Both sexes (male and female)
AFR0380,Access to electricity (% of population),29,Total
AFR0380,Access to electricity (% of population),999,Not Applicable
AFR0381,Life expectancy at birth (years),8,Male
AFR0381,Life expectancy at birth (years),9,Female
AFR0381,Life expectancy at birth (years),28,Both sexes (male and female)
AFR0382,Proportion of women aged 20-24 years who were married or in a union before age 15 (%),9,Female
AFR0382,Proportion of women aged 20-24 years who were married or in a union before age 15 (%),110,Female (20-24 years)
AFR0383,Prevalence of overweight in persons aged 18+years,28,Both sexes (male and female)
AFR0388,GDP growth (annual %),23,Fifth Quintile
AFR0388,GDP growth (annual %),28,Both sexes (male and female)
AFR0388,GDP growth (annual %),999,Not Applicable
AFR0390,Female genital mutilation prevalence (%),9,Female
AFR0390,Female genital mutilation prevalence (%),66,Female (15-49 years)
AFR0391,"School enrolment, primary (% gross)",28,Both sexes (male and female)
AFR0392,"Pre-primary education, duration (years)",28,Both sexes (male and female)
AFR0392,"Pre-primary education, duration (years)",999,Not Applicable
AFR0393,"Secondary education, duration (years)",28,Both sexes (male and female)
AFR0393,"Secondary education, duration (years)",999,Not Applicable
AFR0394,Premature noncommunicable disease (NCD) mortality [SDG 3.4.1],28,Both sexes (male and female)
AFR0394,Premature noncommunicable disease (NCD) mortality [SDG 3.4.1],34,25+ years
AFR0395,HIV incidence rate per 1000 uninfected population [SDG 3.3.1],8,Male
AFR0395,HIV incidence rate per 1000 uninfected population [SDG 3.3.1],9,Female
AFR0395,HIV incidence rate per 1000 uninfected population [SDG 3.3.1],28,Both sexes (male and female)
AFR0395,HIV incidence rate per 1000 uninfected population [SDG 3.3.1],29,Total
AFR0396,Essential medicines readiness,29,Total
AFR0397,"Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease [SDG 3.4.1]",8,Male
AFR0397,"Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease [SDG 3.4.1]",9,Female
AFR0397,"Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease [SDG 3.4.1]",28,Both sexes (male and female)
AFR0398,"Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders [SDG 3.5.1]",28,Both sexes (male and female)
AFR0399,Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis [SDG 3.b.3],28,Both sexes (male and female)
AFR0399,Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis [SDG 3.b.3],999,Not Applicable
AFR0405,Immunization coverage,15,Primary Education
AFR0405,Immunization coverage,68,Secondary or Higher Education
AFR0405,Immunization coverage,999,Not Applicable
AFR0405,Immunization coverage,1018,12-23 months
AFR0406,National Laboratory System Score,999,Not Applicable
AFR0412,Points of Entry (PoE) Score,999,Not Applicable
AFR0414,Radiation Emergencies,999,Not Applicable
AFR0415,Most widely used screening method in national cervical cancer screening program,999,Not Applicable
AFR0416,Type of national cervical cancer screening program,999,Not Applicable
AFR0417,Coverage of national cervical cancer screening program (%),9,Female
AFR0417,Coverage of national cervical cancer screening program (%),999,Not Applicable
AFR0418,Existence of national screening program for cervical cancer,9,Female
AFR0418,Existence of national screening program for cervical cancer,999,Not Applicable
AFR0419,"Proportion of total government spending on essential services (education, health and social protection[SDG1.a.2]",999,Not Applicable
AFR0420,"Proportion of children under 5 years of age who are developmentally on track in health, learning and psychosocialwell-being, by sex",8,Male
AFR0420,"Proportion of children under 5 years of age who are developmentally on track in health, learning and psychosocialwell-being, by sex",9,Female
AFR0420,"Proportion of children under 5 years of age who are developmentally on track in health, learning and psychosocialwell-being, by sex",28,Both sexes (male and female)
AFR0425,Number of cases of poliomyelitis caused by wild poliovirus (WPV),28,Both sexes (male and female)
AFR0425,Number of cases of poliomyelitis caused by wild poliovirus (WPV),1041,0-15 years
AFR0428,Sex ratio at birth,8,Male
AFR0428,Sex ratio at birth,9,Female
AFR0428,Sex ratio at birth,28,Both sexes (male and female)
AFR0429,Population living in urban areas  (%),28,Both sexes (male and female)
AFR0430,National budget allocated to health (%),999,Not Applicable
AFR0431,Top 10 Causes of death,999,Not Applicable
AFR0432,Percentage of children (aged 1-14 years) who experienced any physical punishment and/or psychological aggression by caregivers,8,Male
AFR0432,Percentage of children (aged 1-14 years) who experienced any physical punishment and/or psychological aggression by caregivers,9,Female
AFR0432,Percentage of children (aged 1-14 years) who experienced any physical punishment and/or psychological aggression by caregivers,28,Both sexes (male and female)
AFR0432,Percentage of children (aged 1-14 years) who experienced any physical punishment and/or psychological aggression by caregivers,29,Total
AFR0433,"Percentage of children (aged 36-59 months) developmentally on track in at least 3 of the 4 following domains: literacy-numeracy, physical, social-emotional and learning",8,Male
AFR0433,"Percentage of children (aged 36-59 months) developmentally on track in at least 3 of the 4 following domains: literacy-numeracy, physical, social-emotional and learning",9,Female
AFR0433,"Percentage of children (aged 36-59 months) developmentally on track in at least 3 of the 4 following domains: literacy-numeracy, physical, social-emotional and learning",28,Both sexes (male and female)
AFR0433,"Percentage of children (aged 36-59 months) developmentally on track in at least 3 of the 4 following domains: literacy-numeracy, physical, social-emotional and learning",29,Total
AFR0434,Density of medical doctors (per 10 000 population),28,Both sexes (male and female)
AFR0435,Density of dentists (per 10 000 population ),28,Both sexes (male and female)
AFR0435,Density of dentists (per 10 000 population ),1000,Dentists
AFR0437,Proportion of population using a hand-washing facility with soap and water (%),28,Both sexes (male and female)
AFR0438,Amount of water and sanitation-related official development assistance that is part of a government coordinated spending plan (constant 2017 US $ millions),999,Not Applicable
AFR0439,Prevalence of obesity among children and adolescents (5-19 years)(%),28,Both sexes (male and female)
AFR0440,Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%),70,0-4 years
AFR0441,Proportion of population with large household expenditures on health (greater than 25%) as a share of total household expenditure or income (%),28,Both sexes (male and female)
AFR0441,Proportion of population with large household expenditures on health (greater than 25%) as a share of total household expenditure or income (%),29,Total
AFR0442,"Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) (%)",29,Total
AFR0443,Percentage of facilities offering family planning services,29,Total
AFR0447,Percentage of maternal deaths due to unsafe abortion,9,Female
AFR0447,Percentage of maternal deaths due to unsafe abortion,29,Total
AFR0447,Percentage of maternal deaths due to unsafe abortion,66,Female (15-49 years)
AFR0447,Percentage of maternal deaths due to unsafe abortion,107,Female (10-14 years)
AFR0448,Percentage of women accessing antenatal care services who tested positive for syphilis and were treated,9,Female
AFR0449,Proportion of service delivery points providing post abortion care services and safe abortion where legal,999,Not Applicable
AFR0452,Annual expenditure on family planning from government domestic health budget,999,Not Applicable
AFR0453,Percentage condom use with last high- risk sex amongst AGYW,9,Female
AFR0453,Percentage condom use with last high- risk sex amongst AGYW,29,Total
AFR0454,Antenatal client syphilis screening,9,Female
AFR0455,Percentage of deliveries in health facilities by caesarean section,9,Female
AFR0455,Percentage of deliveries in health facilities by caesarean section,11,Rural
AFR0455,Percentage of deliveries in health facilities by caesarean section,12,Urban
AFR0455,Percentage of deliveries in health facilities by caesarean section,19,First Quintile
AFR0455,Percentage of deliveries in health facilities by caesarean section,20,Second Quintile
AFR0455,Percentage of deliveries in health facilities by caesarean section,22,Fourth Quintile
AFR0455,Percentage of deliveries in health facilities by caesarean section,23,Fifth Quintile
AFR0455,Percentage of deliveries in health facilities by caesarean section,29,Total
AFR0455,Percentage of deliveries in health facilities by caesarean section,1023,Middle
AFR0455,Percentage of deliveries in health facilities by caesarean section,1051,<20years
AFR0455,Percentage of deliveries in health facilities by caesarean section,1056,20-34 years
AFR0455,Percentage of deliveries in health facilities by caesarean section,1057,35-49 years
AFR0456,Annual expenditure on reproductive health from government domestic health budget,999,Not Applicable
AFR0457,Antenatal care attendees who were positive for syphilis (%),9,Female
AFR0458,Comprehensive correct knowledge about AIDS,8,Male
AFR0458,Comprehensive correct knowledge about AIDS,9,Female
AFR0460,Percentage of lower secondary schools providing life skills-based HIV and sexuality education,999,Not Applicable
AFR0461,Percentage of primary schools providing life skills-based HIV and sexuality education,999,Not Applicable
AFR0462,Unmet need for family planning,29,Total
AFR0462,Unmet need for family planning,66,Female (15-49 years)
AFR0462,Unmet need for family planning,73,15-19 years
AFR0462,Unmet need for family planning,74,20-24 years
AFR0462,Unmet need for family planning,75,25-29 years
AFR0462,Unmet need for family planning,76,30-34 years
AFR0462,Unmet need for family planning,77,35-39 years
AFR0462,Unmet need for family planning,78,40-44 years
AFR0462,Unmet need for family planning,79,45-49 years
AFR0462,Unmet need for family planning,129,Married women
AFR0463,Percentage of women with anaemia,42,Female (15+ years)
AFR0464,Percentage of pregnant women with anaemia,42,Female (15+ years)
AFR0467,Maternal Mortality Ratio,9,Female
AFR0468,Number of hospital beds,29,Total
AFR0468,Number of hospital beds,1013,Public sector
AFR0468,Number of hospital beds,1014,Private sector
AFR0469,Number of medical doctors,28,Both sexes (male and female)
AFR0469,Number of medical doctors,29,Total
AFR0470,Number of ICU Beds,29,Total
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,8,Male
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,9,Female
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,11,Rural
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,12,Urban
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,20,Second Quintile
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,22,Fourth Quintile
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,29,Total
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1015,<12 months
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1018,12-23 months
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1019,24-35 months
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1020,36-47 months
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1021,48-59 months
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1022,Lowest
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1023,Middle
AFR0471,Percentage of children under age five who slept under an insecticide treated net (ITN) the night before the survey,1024,Highest
AFR0472,Prevalence of gestational diabetes mellitus,9,Female
AFR0473,Proportion of people with undiagnosed diabetes,28,Both sexes (male and female)
AFR0474,Number of deaths attributable to diabetes,28,Both sexes (male and female)
AFR0475,Share of premature deaths attributed to high body mass index,28,Both sexes (male and female)
AFR0476,General Service Readiness Index,29,Total
AFR0477,The mean availability of items for offering the specific services,29,Total
AFR0478,Availability of Tuberculosis services,29,Total
AFR0479,Availability of Basic obstetric care services,29,Total
AFR0480,Availability of Child health immunization services,29,Total
AFR0481,Absolute number of all cataract operations performed with intraocular lens implantation,28,Both sexes (male and female)
AFR0482,"Absolute number of Allied Eye Health Professionals (ophthalmic nurses, opticians, orthoptists, ophthalmic and optometric assistants or technicians, etc) at country level",28,Both sexes (male and female)
AFR0483,Absolute number of cataract operated people with Visual Acuity >6/18 in the operated eye,28,Both sexes (male and female)
AFR0484,Absolute number of cataracts surgeries performed,28,Both sexes (male and female)
AFR0485,Absolute number of centres offering paediatric ophthalmology services in the country,28,Both sexes (male and female)
AFR0486,Absolute number of centres providing laser treatment for diabetic retinopathy at country level,28,Both sexes (male and female)
AFR0488,Absolute number of Eye care drugs included in the essential medicines list (Please provide a copy of the last updated essential medicines list),28,Both sexes (male and female)
AFR0489,Absolute number of international partners and alliances supporting eye care in the country (Please provide a list of partners and alliances supporting eye care in the country),28,Both sexes (male and female)
AFR0490,Absolute number of meetings of the Prevention of Blindness/ Eye Health committee led by MoH or with the participation of MoH representative and held during last year,28,Both sexes (male and female)
AFR0491,Absolute number of ophthalmologists active at country level,28,Both sexes (male and female)
AFR0492,Absolute number of optometrists at country level,28,Both sexes (male and female)
AFR0493,Absolute number of patient consultations for eye diseases in the country,28,Both sexes (male and female)
AFR0494,Absolute number of people affected by blindness (presenting visual acuity < 3/60 in the better eye) at country level,28,Both sexes (male and female)
AFR0495,Absolute number of people affected by visual impairment (presenting visual acuity < 6/18 in the better eye),28,Both sexes (male and female)
AFR0496,Absolute number of public health facilities that dispense spectacles (glasses) for managing refractive errors at country level,28,Both sexes (male and female)
AFR0497,"Absolute number of visual impaired people, at country level, affected by Blinding trachoma",28,Both sexes (male and female)
AFR0497,"Absolute number of visual impaired people, at country level, affected by Blinding trachoma",1005,Infants (0-6 Months)
AFR0498,"Absolute number of visual impaired people, at country level, affected by Cataract",28,Both sexes (male and female)
AFR0499,"Absolute number of visual impaired people, at country level, affected by Diabetic Retinopathy",28,Both sexes (male and female)
AFR0500,"Absolute number of visual impaired people, at country level, affected by Glaucoma",28,Both sexes (male and female)
AFR0501,"Absolute number of visual impaired people, at country level, affected by Paediatric Eye Diseases",28,Both sexes (male and female)
AFR0502,"Absolute number of visual impaired people, at country level, affected by Uncorrected Refractive Errors",28,Both sexes (male and female)
AFR0503,Do budgetary appropriations for Eye Health exist at MoH level? (Yes/No),999,Not Applicable
AFR0504,Does the National coordinator/focal person for Eye Health exist in the country? (Yes/No),999,Not Applicable
AFR0505,Does the national programme for Community Health Workers include eye health? (Yes/No),999,Not Applicable
AFR0506,"If Yes, is the National Prevention of Blindness/Eye Health plan implemented at Country level? (Yes/No)",999,Not Applicable
AFR0507,Is the National Eye Health plan/strategy compliant with the current National Health strategic Plan? (Yes/No),999,Not Applicable
AFR0508,Is the Primary Eye Care part of the primary health care programme?,999,Not Applicable
AFR0509,Is there a National Prevention of Blindness/Eye Health plan endorsed by Ministry of Health (MoH)? (Yes/No),999,Not Applicable
AFR0510,Observance of World Sight Day with recognition from MoH or other governmental institutions,999,Not Applicable
AFR0511,Coverage of preventive chemotherapy for selected neglected tropical diseases - Lymphatic Filariasis,1038,5 years and above
AFR0512,Coverage of preventive chemotherapy for selected neglected tropical diseases - Onchocerciasis,1038,5 years and above
AFR0513,Coverage of preventive chemotherapy for selected neglected tropical diseases - Schistosomiasis,1038,5 years and above
AFR0514,Coverage of preventive chemotherapy for selected neglected tropical diseases  Soil Transmitted Helminths,1039,5-14 years
AFR0515,Coverage of preventive chemotherapy for selected neglected tropical diseases - Trachoma,1040,Less 6 months
AFR0516,New cases of IHR-notifiable diseases and other notifiable diseases  Yellow fever,8,Male
AFR0516,New cases of IHR-notifiable diseases and other notifiable diseases  Yellow fever,9,Female
AFR0516,New cases of IHR-notifiable diseases and other notifiable diseases  Yellow fever,28,Both sexes (male and female)
AFR0517,New cases of IHR-notifiable diseases and other notifiable diseases  Lassa fever,8,Male
AFR0517,New cases of IHR-notifiable diseases and other notifiable diseases  Lassa fever,9,Female
AFR0517,New cases of IHR-notifiable diseases and other notifiable diseases  Lassa fever,28,Both sexes (male and female)
AFR0518,New cases of IHR-notifiable diseases and other notifiable diseases  Cholera,8,Male
AFR0518,New cases of IHR-notifiable diseases and other notifiable diseases  Cholera,9,Female
AFR0518,New cases of IHR-notifiable diseases and other notifiable diseases  Cholera,1042,>5 years
AFR0518,New cases of IHR-notifiable diseases and other notifiable diseases  Cholera,1043,>2 years
AFR0519,New cases of IHR-notifiable diseases and other notifiable diseases  Meningitis,8,Male
AFR0519,New cases of IHR-notifiable diseases and other notifiable diseases  Meningitis,9,Female
AFR0519,New cases of IHR-notifiable diseases and other notifiable diseases  Meningitis,28,Both sexes (male and female)
AFR0520,New cases of IHR-notifiable diseases and other notifiable diseases  Measles,8,Male
AFR0520,New cases of IHR-notifiable diseases and other notifiable diseases  Measles,9,Female
AFR0520,New cases of IHR-notifiable diseases and other notifiable diseases  Measles,28,Both sexes (male and female)
AFR0521,New cases of IHR-notifiable diseases and other notifiable diseases  Covid-19,8,Male
AFR0521,New cases of IHR-notifiable diseases and other notifiable diseases  Covid-19,9,Female
AFR0521,New cases of IHR-notifiable diseases and other notifiable diseases  Covid-19,28,Both sexes (male and female)
AFR0523,Availability of  Adolescent health services,29,Total
AFR0524,Availability of  Chronic obstructive respiratory disease services,29,Total
AFR0525,Availability of Advanced diagnostic services,29,Total
AFR0526,Availability of Antenatal Care services,29,Total
AFR0527,Availability of ART services,29,Total
AFR0528,Availability of Cardiovascular diseases services,29,Total
AFR0529,Availability of Cervical cancer screening services,29,Total
AFR0530,Availability of Child health preventive and curative care services,29,Total
AFR0531,Availability of Comprehensive emergency obstetric care services,29,Total
AFR0532,Availability of Comprehensive surgery services,29,Total
AFR0533,Availability of Diabetes services,29,Total
AFR0534,Availability of Family planning services,29,Total
AFR0535,Availability of HIV care and support services,29,Total
AFR0536,Availability of HIV counselling and testing services,29,Total
AFR0537,availability of items for offering Adolescent health services,29,Total
AFR0538,availability of items for offering Advanced diagnostic services services,29,Total
AFR0539,availability of items for offering Antenatal care services,29,Total
AFR0540,availability of items for offering ART services,29,Total
AFR0541,availability of items for offering Basic obstetric care services,29,Total
AFR0542,availability of items for offering Basic surgery services,29,Total
AFR0543,availability of items for offering Blood transfusion services,29,Total
AFR0544,availability of items for offering Cardiovascular diseases services,29,Total
AFR0545,availability of items for offering Cervical cancer screening services,29,Total
AFR0546,availability of items for offering Child immunization services,29,Total
AFR0547,availability of items for offering Chronic obstructive respiratory disease services,29,Total
AFR0548,Availability of STIs services,29,Total
AFR0549,Availability of Preventive & curative services,29,Total
AFR0550,Availability of PMTCT services,29,Total
AFR0551,Availability of Malaria Services,29,Total
AFR0552,Availability of Lifesaving commodities for mothers services,29,Total
AFR0553,Availability of Lifesaving commodities for children services,29,Total
AFR0554,availability of items for offering Comprehensive surgery services,29,Total
AFR0555,availability of items for offering Diabetes services,29,Total
AFR0556,availability of items for offering Family planning services,29,Total
AFR0557,availability of items for offering High-level diagnostic services services,29,Total
AFR0558,availability of items for offering HIV care and support services,29,Total
AFR0559,availability of items for offering HIV counseling and testing services,29,Total
AFR0560,availability of items for offering Life-saving medicine (children) services,29,Total
AFR0561,availability of items for offering Life-saving medicines (mothers) services,29,Total
AFR0562,availability of items for offering Malaria services,29,Total
AFR0563,availability of items for offering PMTCT services,29,Total
AFR0564,availability of items for offering Preventive and curative services for under-fives,29,Total
AFR0565,availability of items for offering TB services,29,Total
AFR0566,availability of items for offering STIs services,29,Total
AFR0567,UHC - Service coverage sub-index on Noncommunicable diseases,28,Both sexes (male and female)
AFR0568,UHC - Service coverage sub-index on Service capacity and access,28,Both sexes (male and female)
AFR0569,UHC - Service coverage sub-index on Infectious Diseases,28,Both sexes (male and female)
AFR0570,"UHC - Service coverage sub-index on reproductive, maternal, newborn and child health",28,Both sexes (male and female)
AFR0592,health system performance (index),999,Not Applicable
AFR0593,Access to health services,999,Not Applicable
AFR0594,Demand for health services,999,Not Applicable
AFR0595,Quality of care,999,Not Applicable
AFR0596,Health system resilience (Index),999,Not Applicable
AFR0597,Inherent resilience,999,Not Applicable
AFR0598,Physical access score,999,Not Applicable
AFR0599,Financial access score,999,Not Applicable
AFR0600,Sociocultural access score,999,Not Applicable
AFR0601,User experience score,999,Not Applicable
AFR0602,Care effectiveness score,999,Not Applicable
AFR0603,Healthy actions score,999,Not Applicable
AFR0604,Health seeking score,999,Not Applicable
AFR0605,Country size,999,Not Applicable
AFR0606,Demographic growth,999,Not Applicable
AFR0607,Density of population,999,Not Applicable
AFR0608,GDP per capita,999,Not Applicable
AFR0609,Inflation rate,999,Not Applicable
AFR0610,Human Development Index,999,Not Applicable
AFR0611,"National legislation, policy and financing-score",29,Total
AFR0612,Zoonotic events and the human-animal interface-score,29,Total
AFR0613,Food safety-score,29,Total
AFR0614,Chemical events-score,29,Total
AFR0615,Human resources-score,29,Total
AFR0616,National health emergency framework-score,29,Total
AFR0617,Health service provision-score,29,Total
AFR0618,"Annual mean levels of fine particulate matter (population-weighted), by location (micrograms per cubic meter)- SDG 11.6.2",11,Rural
AFR0618,"Annual mean levels of fine particulate matter (population-weighted), by location (micrograms per cubic meter)- SDG 11.6.2",12,Urban
AFR0618,"Annual mean levels of fine particulate matter (population-weighted), by location (micrograms per cubic meter)- SDG 11.6.2",29,Total
AFR0620,Proportion of children aged 1-14 years who experienced physical punishment and/or psychological aggression by caregivers in last month (% of children aged 1-14 years)-SDG 16.2.1,1091,1-14 years
AFR0620,Proportion of children aged 1-14 years who experienced physical punishment and/or psychological aggression by caregivers in last month (% of children aged 1-14 years)-SDG 16.2.1,1092,2-14 years
AFR0621,Proportion of women aged 15-49 years with anaemia (%)-SDG 2.2.3,9,Female
AFR0622,"Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%)-SDG 3.d.2",29,Total
AFR0623,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%)-SDG 3.d.2,29,Total
AFR0624,"Proportion of women who make their own informed decisions regarding sexual relations, contraceptive use and reproductive health care (% of women aged 15-49 years)-SDG 5.6.1",9,Female
AFR0625,"Extent to which countries have laws and regulations that guarantee full and equal access to women and men aged 15 years and older to sexual and reproductive health care, information and education (%)-SDG 5.6.2",29,Total
AFR0626,"Fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",8,Male
AFR0626,"Fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",9,Female
AFR0626,"Fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",28,Both sexes (male and female)
AFR0627,"Non-fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",8,Male
AFR0627,"Non-fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",9,Female
AFR0627,"Non-fatal occupational injuries among employees, by sex and migrant status (per 100,000 employees)-SDG 8.8.1",28,Both sexes (male and female)
AFR0628,"Proportion of population subjected to physical violence in the previous 12 months, by sex (%)-SDG 16.1.3",8,Male
AFR0628,"Proportion of population subjected to physical violence in the previous 12 months, by sex (%)-SDG 16.1.3",9,Female
AFR0628,"Proportion of population subjected to physical violence in the previous 12 months, by sex (%)-SDG 16.1.3",28,Both sexes (male and female)
AFR0629,"Proportion of population subjected to sexual violence in the previous 12 months, by sex (%)-SDG 16.1.3",8,Male
AFR0629,"Proportion of population subjected to sexual violence in the previous 12 months, by sex (%)-SDG 16.1.3",9,Female
AFR0629,"Proportion of population subjected to sexual violence in the previous 12 months, by sex (%)-SDG 16.1.3",28,Both sexes (male and female)
AFR0630,"Detected victims of human trafficking, by age and sex (number)-SDG 16.2.2",29,Total
AFR0631,Countries that have conducted at least one population and housing census in the last 10 years (1 = YES; 0 = NO)-SDG 17.19.2a,29,Total
AFR0632,Countries with death registration data that are at least 75 percent complete (1 = YES; 0 = NO)-SDG 17.19.2b,29,Total
AFR0633,Immunization coverage rate for Meningitis,29,Total
AFR0633,Immunization coverage rate for Meningitis,1098,Administrative coverage
AFR0633,Immunization coverage rate for Meningitis,1099,Official coverage
AFR0634,Availability of estimates on impoverishment due to out-of-pocket health expenditures,23,Fifth Quintile
AFR0635,Preterm birth rate (per 100 live births),23,Fifth Quintile
AFR0636,Poverty rate,999,Not Applicable
AFR0638,Number of Regions or Provinces,999,Not Applicable
AFR0639,Number of health districts,999,Not Applicable
AFR0640,"Prevalence of moderate or severe food insecurity in the population, based on the food insecurity experience scale [FIES][SDG 2.1.2]",28,Both sexes (male and female)
AFR0640,"Prevalence of moderate or severe food insecurity in the population, based on the food insecurity experience scale [FIES][SDG 2.1.2]",42,Female (15+ years)
AFR0640,"Prevalence of moderate or severe food insecurity in the population, based on the food insecurity experience scale [FIES][SDG 2.1.2]",45,Male (15+ years)
AFR0641,Countries with birth registration data that are at least 90 percent complete (1 = YES; 0 = NO)-SDG 17.19.2b,29,Total
AFR0642,Immunization coverage rate for Yellow fever,1098,Administrative coverage
AFR0642,Immunization coverage rate for Yellow fever,1099,Official coverage
AFR0642,Immunization coverage rate for Yellow fever,1100,WHO/UNICEF estimates of National immunization coverage
AFR0643,"Prevention of HIV in key populations (Sex workers, men who have sex with men, people who inject drugs, prisoners, transgender people) - %",1101,Sex workers
AFR0643,"Prevention of HIV in key populations (Sex workers, men who have sex with men, people who inject drugs, prisoners, transgender people) - %",1102,Men who have sex with men
AFR0643,"Prevention of HIV in key populations (Sex workers, men who have sex with men, people who inject drugs, prisoners, transgender people) - %",1103,People who inject drugs
AFR0643,"Prevention of HIV in key populations (Sex workers, men who have sex with men, people who inject drugs, prisoners, transgender people) - %",1105,Transgender people
AFR0644,Prevalence of births with defects/anomalies (per 1 million births),8,Male
AFR0644,Prevalence of births with defects/anomalies (per 1 million births),9,Female
AFR0644,Prevalence of births with defects/anomalies (per 1 million births),28,Both sexes (male and female)
AFR0645,Prevalence of congenital heart defects (per 1 million births),8,Male
AFR0645,Prevalence of congenital heart defects (per 1 million births),9,Female
AFR0645,Prevalence of congenital heart defects (per 1 million births),28,Both sexes (male and female)
AFR0646,Prevalence of congenital neurotube defects/anomalies (per 1 million births),8,Male
AFR0646,Prevalence of congenital neurotube defects/anomalies (per 1 million births),9,Female
AFR0646,Prevalence of congenital neurotube defects/anomalies (per 1 million births),28,Both sexes (male and female)
AFR0647,Number Specialists doctors,28,Both sexes (male and female)
AFR0648,Density of specialists doctors (per 1000 population),28,Both sexes (male and female)
AFR0649,Number of new HIV infections,28,Both sexes (male and female)
AFR0650,Number of suicides,8,Male
AFR0650,Number of suicides,9,Female
AFR0650,Number of suicides,28,Both sexes (male and female)
AFR0651,Age-standardized suicide rates (per 100 000),8,Male
AFR0651,Age-standardized suicide rates (per 100 000),9,Female
AFR0651,Age-standardized suicide rates (per 100 000),28,Both sexes (male and female)
